Eberconazole

Eberconazole
Clinical data
Trade names	Ebernet
Legal status
Legal status	US: Not FDA approved;
Identifiers
	IUPAC name 1-(1,3-Dichloro-6,11-dihydro-5H-dibenzo[1,2-a:1',4'-e] [7]annulen-11-yl)imidazole;
CAS Number	128326-82-9;
PubChem CID	72051;
ChemSpider	65038;
UNII	V7O1U41C9B;
CompTox Dashboard (EPA)	DTXSID90926104 ;
Chemical and physical data
Formula	C18H14Cl2N2
Molar mass	329.22 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC2=CC(=CC(=C2C(C3=CC=CC=C31)N4C=CN=C4)Cl)Cl;
	InChI InChI=1S/C18H14Cl2N2/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22/h1-4,7-11,18H,5-6H2; Key:MPTJIDOGFUQSQH-UHFFFAOYSA-N;

Eberconazole is an antifungal drug. As a 1% topical cream, it is an effective treatment for dermatophytosis, candidiasis, and pityriasis.

It was approved for use in Spain in 2015 and is sold under the trade name Ebernet. It is also approved for use in Panama, Guatemala, Costa Rica, Honduras, and the Dominican Republic.

References

1 2 "Ebernet". NewBridge Pharmaceuticals. Archived from the original on 2016-04-24. Retrieved 2017-01-15.
↑ del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E (2001). "A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections". Mycoses. 44 (5): 173–80. doi:10.1046/j.1439-0507.2001.00632.x. PMID 11486455.
↑ Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR (May 2006). "Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream". International Journal of Dermatology. 45 (5): 600–4. doi:10.1111/j.1365-4632.2006.02841.x. PMID 16700802.
↑ "Eberconazole". Drugs.com. Archived from the original on 2021-01-17. Retrieved 2017-01-15.

This dermatologic drug article is a stub. You can help Wikipedia by adding missing information.

[nbpharma-1] 1 2 "Ebernet". NewBridge Pharmaceuticals. Archived from the original on 2016-04-24. Retrieved 2017-01-15.

[2] Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E (2001). "A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections". Mycoses. 44 (5): 173–80. doi:10.1046/j.1439-0507.2001.00632.x. PMID 11486455.

[3] Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR (May 2006). "Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream". International Journal of Dermatology. 45 (5): 600–4. doi:10.1111/j.1365-4632.2006.02841.x. PMID 16700802.

[4] "Eberconazole". Drugs.com. Archived from the original on 2021-01-17. Retrieved 2017-01-15.